Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3

Stable Identifier
R-HSA-5655323
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Once recruited to the activated receptor, PI3K phosphorylates PIP2 to PIP3, leading to activation of AKT signaling. PI3K signaling has been demonstrated in ZMYM2-, FOP- and BCR-FGFR1 fusions (Chen, 2004; Demiroglu, 2001; Guasch, 2001), as well as downstream of a number of other FGFR mutants (see for instance, Byron, 2008; Kunii, 2008; Agazie, 2003; Takeda, 2007).

Literature References
PubMed ID Title Journal Year
17505008 AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

Takeda, M, Arao, T, Yokote, H, Komatsu, T, Yanagihara, K, Sasaki, H, Yamada, Y, Tamura, T, Fukuoka, K, Kimura, H, Saijo, N, Nishio, K

Clin Cancer Res 2007
11689702 8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways

Guasch, G, Ollendorff, V, Borg, JP, Birnbaum, D, P├ębusque, MJ

Mol Cell Biol 2001
18757403 Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

Byron, SA, Gartside, MG, Wellens, CL, Mallon, MA, Keenan, JB, Powell, MA, Goodfellow, PJ, Pollock, PM

Cancer Res 2008
11739186 The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

Demiroglu, A, Steer, EJ, Heath, C, Taylor, K, Bentley, M, Allen, SL, Koduru, P, Brody, JP, Hawson, G, Rodwell, R, Doody, ML, Carnicero, F, Reiter, A, Goldman, JM, Melo, JV, Cross, NC

Blood 2001
15448205 PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

Chen, J, Deangelo, DJ, Kutok, JL, Williams, IR, Lee, BH, Wadleigh, M, Duclos, N, Cohen, S, Adelsperger, J, Okabe, R, Coburn, A, Galinsky, I, Huntly, B, Cohen, PS, Meyer, T, Fabbro, D, Roesel, J, Banerji, L, Griffin, JD, Xiao, S, Fletcher, JA, Stone, RM, Gilliland, DG

Proc Natl Acad Sci U S A 2004
14534538 The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3

Agazie, YM, Movilla, N, Ischenko, I, Hayman, MJ

Oncogene 2003
18381441 FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

Kunii, K, Davis, L, Gorenstein, J, Hatch, H, Yashiro, M, Di Bacco, A, Elbi, C, Lutterbach, B

Cancer Res 2008
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
phosphatidylinositol-4,5-bisphosphate 3-kinase activity of Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PI3K [plasma membrane]
Physical Entity
Activity
Normal reaction
Disease
Name Identifier Synonyms
bone development disease 0080006
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created